{"id":"W4408853818","doi":"10.1038/s44276-025-00133-6","title":"A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers","year":2025,"lang":"en","type":"article","venue":"BJC Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"FP7 Health; RECETOX Přírodovědecké Fakulty Masarykovy Univerzity; Takeda Oncology; Chugai Pharmaceutical; Bristol-Myers Squibb; Samsung; University of Oxford; Genentech; Cancer Research UK; Aptitude Health; Daiichi Sankyo Europe; Gilead Sciences; Servier; Queen's University; Merck KGaA; Ministerstvo Školství, Mládeže a Tělovýchovy; National Institute for Health and Care Research; Queen's University Belfast; Seagen; European Commission; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Les Laboratories Pierre Fabre; AstraZeneca","keywords":"Crizotinib; Tolerability; Medicine; Adverse effect; Internal medicine; Pharmacokinetics; Toxicity; Clinical trial; Oncology; Pharmacology; Colorectal cancer; ALK inhibitor; MEK inhibitor; Cancer; Lung cancer; Kinase; MAPK/ERK pathway; Chemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001852975,0.000190533,0.0002327863,0.00004389632,0.0000948325,0.00001497592,0.0001624578,0.00007203032,0.000005071322],"category_scores_gemma":[0.00006694133,0.00009886539,0.00005069181,0.0002601979,0.00009275235,0.000006257417,0.0001307977,0.0001211839,2.659737e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003327437,"about_ca_system_score_gemma":0.0003266071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001119446,"about_ca_topic_score_gemma":0.000895103,"domain_scores_codex":[0.9986348,0.00008014626,0.0003737941,0.0004161458,0.000269083,0.0002259869],"domain_scores_gemma":[0.9987105,0.00001151359,0.0003242142,0.000760694,0.0001508225,0.00004226219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004120612,0.005046597,0.7506798,0.0001269141,0.0004748094,0.0002126688,0.001701872,0.0007019038,0.2205422,0.00002867259,0.00763299,0.008731028],"study_design_scores_gemma":[0.02021434,0.01481866,0.2505359,0.0004161217,0.0002578758,0.00004436015,0.003284297,0.00001081563,0.6840114,0.00003611436,0.02565804,0.0007120984],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972742,0.00009625275,0.00001957117,0.00006327293,0.0003317562,0.001170432,0.00001321836,0.000007958626,0.001023374],"genre_scores_gemma":[0.9991345,0.00000357907,0.00004450885,0.000125939,0.00006566395,0.0001383752,0.0000260856,0.0000182842,0.000443081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5001439,"threshold_uncertainty_score":0.4031614,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004268398584754407,"score_gpt":0.2552967227798368,"score_spread":0.2510283241950824,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}